ISSN: 1885-5857 Impact factor 2023 7.2
Vol. 70. Num. 4.
Pages 309-310 (April 2017)

Corrections
Correction in the Spanish translation of the article by Ponikowski et al. “2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure”, Rev Esp Cardiol. 2016;69:1167.e1-e85

Corrección en la traducción al español del artículo de Ponikowski et al. “Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica”, Rev Esp Cardiol. 2016;69:1167.e1-e85

Rev Esp Cardiol. 2016;69:116710.1016/j.rec.2016.11.005
Piotr Ponikowski, Adriaan A. Voors, Stefan D. Anker, Héctor Bueno, John G.F. Cleland, Andrew J.S. Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A. Jankowska, Mariell Jessup, Cecilia Linde, Petros Nihoyannopoulos, John T. Parissis, Burkert Pieske, Jillian P. Riley, Giuseppe M.C. Rosano, Luis M. Ruilope, Frank Ruschitzka, Frans H. Rutten, Peter van der Meer

Options

In the article by Ponikowski et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur Heart J. 2016;37:2129-2200, the following sentence, which appeared in the ahead of print version, has been eliminated: “In the SIGNIFY trial in patients with activity-limiting angina without HF, ivabradine increased the risk of death from cardiovascular causes or non-fatal myocardial infarction and therefore is not recommended in this setting.”

The Spanish translation of the guideline, published in Rev Esp Cardiol. 2016;69:1167.e1-e85, was based on the first ahead of print version. After the publication of the correct print version in European Heart Journal and communication of this discrepancy, the translation of this sentence was eliminated from the electronic version of the article on February 23, 2017.

Are you a healthcare professional authorized to prescribe or dispense medications?